Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
NCT05469893
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is testing two drugs to see which one works better for people with a kind of cancer called smoldering multiple myeloma. The first drug is Teclistamab and the second is a combination of Lenalidomide and Dexamethasone. People with smoldering multiple myeloma are at risk for getting worse, but often don't have symptoms. The goal is to find a treatment for this kind of cancer, which currently doesn't have an approved therapy.
This study is testing two drugs to see which one works better for people with a kind of cancer called smoldering multiple myeloma. The first drug is Teclistamab and the second is a combination of Lenalidomide and Dexamethasone. People with smoldering multiple myeloma are at risk for getting worse, but often don't have symptoms. The goal is to find a treatment for this kind of cancer, which currently doesn't have an approved therapy.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: * Teclistamab * Lenalidomide (also called Revlimid) * Dexamethasone (also called Decadron)
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: * Teclistamab * Lenalidomide (also called Revlimid) * Dexamethasone (also called Decadron)
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
